Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

Jan 9, 2025 · Intellia is building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments. We bring new hope for people living with conditions, including …

Feb 27, 2025 · CAMBRIDGE, Mass. , Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on …

The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.

Learn more about Intellia, a clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR.

Today, scientists at Intellia are developing this technology to make targeted changes to genes directly implicated in human disease. In the future, Intellia hopes to use its CRISPR technology …

Intellia is committed to developing gene editing treatments for those living with severe and life-threatening genetic diseases. We are currently investigating our CRISPR-based technology in …

Intellia is engineering T cells against specific cancer antigens. therapies to provide them with particular enhanced attributes that may more effectively treat oncological and autoimmune …

At Intellia, we focus on identifying opportunities that can positively transform the lives of people living with severe and life-threatening conditions. Learn more about the diseases we’re …